Suven Life Sciences Ltd vs Tejnaksh Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Suven Life Sciences Ltd is ₹ 258.1 as of 30 Oct 15:30 . The P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Tejnaksh Healthcare Ltd changed from 36 on March 2021 to 19.9 on March 2026 . This represents a CAGR of -9.41% over 6 years The Market Cap of Suven Life Sciences Ltd changed from ₹ 896.07 crore on March 2021 to ₹ 3503 crore on March 2026 . This represents a CAGR of 25.51% over 6 yearsThe Market Cap of Tejnaksh Healthcare Ltd changed from ₹ 73.94 crore on March 2021 to ₹ 24.23 crore on March 2026 . This represents a CAGR of -16.97% over 6 years The revenue of Suven Life Sciences Ltd for the Jun '26 is ₹ 11.09 crore as compare to the Mar '26 revenue of ₹ 8.3 crore. This represent the growth of 33.61% The revenue of Tejnaksh Healthcare Ltd for the Jun '26 is ₹ 2.75 crore as compare to the Mar '26 revenue of ₹ 2.69 crore. This represent the growth of 2.23% The ebitda of Suven Life Sciences Ltd for the Jun '26 is ₹ -124 crore as compare to the Mar '26 ebitda of ₹ -43.86 crore. This represent the growth of 184.95% The ebitda of Tejnaksh Healthcare Ltd for the Jun '26 is ₹ 0.79 crore as compare to the Mar '26 ebitda of ₹ 0.85 crore. This represent the decline of -7.06% The net profit of Suven Life Sciences Ltd changed from ₹ -28.04 crore to ₹ -127 crore over 9 quarters. This represents a CAGR of 96.11% The net profit of Tejnaksh Healthcare Ltd changed from ₹ 0.6 crore to ₹ 0.26 crore over 9 quarters. This represents a CAGR of -31.04% The Dividend Payout of Suven Life Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Tejnaksh Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Suven Life Sciences Ltd

Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989.
The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003.
Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider. The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies. The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors.

About Tejnaksh Healthcare Ltd

Tejnaksh Healthcare Limited was incorporated in Mumbai on 18 February, 2008 as a Private Limited Company and converted into Public Limited Company with effect from 10 March, 2015 issued by the Registrar of Companies, Mumbai, Maharashtra.
Tejnaksh runs an Institute of Urology, an ISO certified the international level Urology hospital, located in Dhule, Maharashtra.
It provides a complete range of services from consultations and investigations to treatment for Urology.
The main objective of Hospital namely Institute of Urology is to provide the people of Khandesh region of Maharashtra, the services of a super specialty hospital at an affordable rate. Initiated with a vision to strengthen healthcare in rural India, the Company started its journey from Institute of Urology, a state of the art flagship, kidney care center in Dhule in the year 2003.

FAQs for the comparison of Suven Life Sciences Ltd and Tejnaksh Healthcare Ltd

Which company has a larger market capitalization, Suven Life Sciences Ltd or Tejnaksh Healthcare Ltd?

Market cap of Suven Life Sciences Ltd is 7,292 Cr while Market cap of Tejnaksh Healthcare Ltd is 26 Cr

What are the key factors driving the stock performance of Suven Life Sciences Ltd and Tejnaksh Healthcare Ltd?

The stock performance of Suven Life Sciences Ltd and Tejnaksh Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Life Sciences Ltd and Tejnaksh Healthcare Ltd?

As of October 31, 2026, the Suven Life Sciences Ltd stock price is INR ₹258.1. On the other hand, Tejnaksh Healthcare Ltd stock price is INR ₹12.83.

How do dividend payouts of Suven Life Sciences Ltd and Tejnaksh Healthcare Ltd compare?

To compare the dividend payouts of Suven Life Sciences Ltd and Tejnaksh Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.